Abstract 2101: The growth of a xenograft breast cancer tumor model with engineered hyaluronan-accumulating stroma is dependent on hyaluronan and independent of CD44

The abnormal accumulation of hyaluronan in the solid tumor microenvironment is associated with poor prognosis in several human cancers. Hyaluronan often accumulates in the tumor stroma. To understand the role of hyaluronan-accumulating stroma in tumor progression, we engineered a hyaluronan-producing fibroblast cell line 3T3HAS3 by lentiviral transduction of the human hyaluronan synthase 3 gene into Balb/c 3T3 cells. The 3T3HAS3 cells produced significant amounts of hyaluronan in vitro, which bind to the cell surface of the human breast cancer cell line MDA-MB-468. When co-grafted with MDA-MB-468 cells in nude mice, 3T3HAS3 significantly enhanced tumor growth. Immunohistochemical analysis of tumor xenografts showed that MDA-MB-468 cells were surrounded by hyaluronan-accumulating stroma, closely resembling the morphology observed in human breast cancer specimens. Tumor growth of this co-graft model required hyaluronan production from 3T3HAS3 cells, as demonstrated by the delayed tumor growth upon hyaluronan removal by expression of the human PH20 gene in 3T3HAS3 cells, or by systemic administration of PEGylated recombinant human PH20 (PEGPH20). In contrast, neither the expression of CD44, a well-characterized hyaluronan receptor, in tumor and stromal fibroblasts, nor the binding of hyaluronan to CD44 in MDA-MB-468 tumor cells was essential for tumor growth. Small scale screening of signaling changes in xenograft tumors suggested that the AMPK/mTOR pathway may respond to hyaluronan removal by PEGPH20. Collectively, these data demonstrate that the growth of an engineered breast cancer xenograft model with hyaluronan-accumulating stroma is dependent on hyaluronan, and that hyaluronan-CD44 interaction may not be the main mechanism through which hyaluronan promotes tumor progression in certain tumors. Citation Format: Chunmei Zhao, Benjamin J. Thompson, Kelly Chen, Mathieu Marella, Susan Zimmerman, Trevor Kimbler, Barbara Blouw, Sheryl Garrovillo, Lei Huang, Adrian Radi, Zhongdong Huang, H. Michael Shepard, Sanna Rosengren, Christopher D. Thanos, Daniel C. Maneval. The growth of a xenograft breast cancer tumor model with engineered hyaluronan-accumulating stroma is dependent on hyaluronan and independent of CD44 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2101.

[1]  M. Tammi,et al.  Activated hyaluronan metabolism in the tumor matrix - Causes and consequences. , 2019, Matrix biology : journal of the International Society for Matrix Biology.

[2]  M. Sharpley,et al.  Extracellular Matrix Remodeling Regulates Glucose Metabolism through TXNIP Destabilization , 2018, Cell.

[3]  D. V. Von Hoff,et al.  Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression , 2018, Clinical Cancer Research.

[4]  Lei Zheng,et al.  HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Wong,et al.  Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20) , 2017, Current Oncology Reports.

[6]  N. Itano,et al.  Hyaluronan: A modulator of the tumor microenvironment. , 2016, Cancer letters.

[7]  N. Sato,et al.  Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma , 2016, Acta pharmaceutica Sinica. B.

[8]  H. Shepard.  Hyaluronan : A Key Component of the Tumor Microenvironment and Promising Therapeutic Target Hyaluronan and its Binding Partners , 2015 .

[9]  E. Puré,et al.  Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. , 2015, Cancer research.

[10]  E. Puré,et al.  Hyaluronan – A Functional and Structural Sweet Spot in the Tissue Microenvironment , 2015, Front. Immunol..

[11]  M. Tammi,et al.  Fluorescence Resonance Energy Transfer (FRET) and Proximity Ligation Assays Reveal Functionally Relevant Homo- and Heteromeric Complexes among Hyaluronan Synthases HAS1, HAS2, and HAS3* , 2015, The Journal of Biological Chemistry.

[12]  Fabian Birzele,et al.  CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients , 2015, Clinical Cancer Research.

[13]  Caroline H. Diep,et al.  Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer , 2015, Clinical Cancer Research.

[14]  G. Wahl,et al.  Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy , 2014, Cell.

[15]  D. Tuveson,et al.  Accumulation of Extracellular Hyaluronan by Hyaluronan Synthase 3 Promotes Tumor Growth and Modulates the Pancreatic Cancer Microenvironment , 2014, BioMed research international.

[16]  H. Shepard,et al.  Characterization of a Novel Recombinant Hyaluronan Binding Protein for Tissue Hyaluronan Detection , 2014, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  N. Takakura,et al.  CD44 Expressed on Cancer‐Associated Fibroblasts Is a Functional Molecule Supporting the Stemness and Drug Resistance of Malignant Cancer Cells in the Tumor Microenvironment , 2014, Stem cells.

[18]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[19]  A. Mannermaa,et al.  Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer , 2013, International journal of cancer.

[20]  Triantafyllos Stylianopoulos,et al.  Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors , 2012, Proceedings of the National Academy of Sciences.

[21]  M. Bonn,et al.  Hydration dynamics of hyaluronan and dextran. , 2012, Biophysical journal.

[22]  Derek S. Chan,et al.  Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer , 2012, Gut.

[23]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[24]  J. Schroeder,et al.  Understanding the Dual Nature of CD44 in Breast Cancer Progression , 2011, Molecular Cancer Research.

[25]  R. Markwald,et al.  Hyaluronan–CD44 interactions as potential targets for cancer therapy , 2011, The FEBS journal.

[26]  V. Kosma,et al.  Hyaluronan in human malignancies. , 2011, Experimental cell research.

[27]  P. O'Connor,et al.  Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models , 2010, Molecular Cancer Therapeutics.

[28]  B. Toole.  Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities , 2009, Clinical Cancer Research.

[29]  R. Weinberg,et al.  Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 Expression , 2008, Cell.

[30]  M. Abdraboh,et al.  In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. , 2007, The American journal of pathology.

[31]  R. Kannagi,et al.  Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. , 2007, The American journal of pathology.

[32]  J. Lin,et al.  Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer , 2005, British Journal of Cancer.

[33]  V. Lokeshwar,et al.  HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. , 2005, Cancer research.

[34]  J. López,et al.  CD44 attenuates metastatic invasion during breast cancer progression. , 2005, Cancer research.

[35]  Rebecca L. Jones,et al.  Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer. , 2005, Gynecologic oncology.

[36]  Terry L. Smith,et al.  CD44 Expression Is Associated with Increased Survival in Node-Negative Invasive Breast Carcinoma , 2005, Clinical Cancer Research.

[37]  M. Simpson,et al.  Hyaluronan synthase‐3 is upregulated in metastatic colon carcinoma cells and manipulation of expression alters matrix retention and cellular growth , 2003, International journal of cancer.

[38]  S. Ghatak,et al.  Elevated Hyaluronan Production Induces Mesenchymal and Transformed Properties in Epithelial Cells* , 2003, Journal of Biological Chemistry.

[39]  T. Mak,et al.  Absence of the CD44 gene prevents sarcoma metastasis. , 2002, Cancer research.

[40]  F. Gao,et al.  Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. , 2001, Cancer research.

[41]  V. Kosma,et al.  High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. , 2001, European journal of cancer.

[42]  V. Kosma,et al.  Prognostic value of hyaluronan expression in non‐small‐cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma , 2001, International journal of cancer.

[43]  A. Theocharis,et al.  Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. , 2000, Biochimica et biophysica acta.

[44]  V. Kosma,et al.  Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. , 2000, The American journal of pathology.

[45]  V. Kosma,et al.  Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate , 1999, British Journal of Cancer.

[46]  V. Kosma,et al.  Expression of hyaluronan in benign and malignant breast lesions , 1997, International journal of cancer.

[47]  R. Stern,et al.  A microtiter-based assay for hyaluronidase activity not requiring specialized reagents. , 1997, Analytical biochemistry.

[48]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[49]  M. Tammi,et al.  Hyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancers. , 1996, The American journal of pathology.

[50]  J. Roboz,et al.  Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma. , 1985, Cancer research.

[51]  M. Tempero,et al.  HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. , 2017, Future oncology.

[52]  J. Sleeman,et al.  CD44 is a multidomain signaling platform that integrates extracellular matrix cues with growth factor and cytokine signals. , 2014, Advances in cancer research.

[53]  A. Mannermaa,et al.  Hyaluronan synthases (HAS1–3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival , 2013, Breast Cancer Research and Treatment.

[54]  V. Kosma,et al.  High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. , 2000, Cancer research.